UCB struck a global licensing deal with Antengene to acquire development and commercialization rights to ATG-201, a CD19/CD3 bispecific T‑cell engager for autoimmune diseases. Antengene will run early trials in China and Australia while UCB takes over global development and manufacturing thereafter. The agreement includes $60M upfront and up to $1.1B+ in milestones, signaling big pharma commitment to TCEs for immunology. The transaction pairs UCB’s biologics and commercialization scale with Antengene’s AnTenGager masking technology designed to improve safety and manufacturability. Alistair Henry, UCB’s CSO, framed the deal as a strategic entry into an emerging, potentially disruptive therapeutic class. The timeline contemplates first‑in‑human evaluation led by Antengene followed by an accelerated handoff for global late‑stage development.